Novel Psilocin Prodrugs for Treatment-Resistant Anxiety Disorders

Поділитися
Вставка
  • Опубліковано 15 гру 2024

КОМЕНТАРІ • 5

  • @chemistrycapital
    @chemistrycapital 9 місяців тому +3

    Saw this article a while ago. It's great that you've made an easy to understand video on it!

  • @RalfStephan
    @RalfStephan 9 місяців тому

    Very informative about the lab methods used in this type of research, many thanks

  • @user-mp4bc9qp2x
    @user-mp4bc9qp2x 9 місяців тому

    i'm not sure if they cover this in the paper, but is there a reason they want to administer a prodrug at all? why not just give the API and you wouldn't have metabolism issue etc.

  • @RalfStephan
    @RalfStephan 9 місяців тому

    There is still the question if a shorter psilocin exposure can have the same therapeutic effect, which I doubt

    • @nervonabliss
      @nervonabliss 9 місяців тому

      I think that will depend on the setting and application of therapy. I believe determining what will be most efficient for each individual patient will be more difficult.